Stockscreener 앱 받기
0.3334
2.22%
-0.0046
전일 마감가:
$0.338
열려 있는:
$0.34
하루 거래량:
27,550
Relative Volume:
0.16
시가총액:
$16.47M
수익:
-
순이익/손실:
$-74.56M
주가수익비율:
-0.182
EPS:
-1.8316
순현금흐름:
$-60.27M
1주 성능:
-10.68%
1개월 성능:
+6.96%
6개월 성능:
-65.57%
1년 성능:
-75.70%
1일 변동 폭
$0.327
$0.34
1주일 범위
$0.321
$0.3796
52주 변동 폭
$0.2201
$1.54
Rallybio Corp Stock (RLYB) Company Profile
명칭
Rallybio Corp
전화
203- 859-3820
주소
234 CHURCH STREET, NEW HAVEN
RLYB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
0.3305 | 16.47M | 0 | -74.56M | -60.27M | -1.8316 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.68 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
543.24 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
319.84 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
558.74 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
243.00 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-09 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-05-15 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-02-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-04-17 | 개시 | H.C. Wainwright | Buy |
| 2023-04-10 | 개시 | Wedbush | Outperform |
| 2022-12-09 | 개시 | JP Morgan | Overweight |
| 2022-02-22 | 개시 | JMP Securities | Mkt Outperform |
| 2021-08-23 | 개시 | Cowen | Outperform |
| 2021-08-23 | 개시 | Evercore ISI | Outperform |
| 2021-08-23 | 개시 | Jefferies | Buy |
모두보기
Rallybio Corp 주식(RLYB)의 최신 뉴스
Affibody’s licensee Rallybio Announces Initiation of Dosing with RLYB116 in Phase 1 Confirmatory PK/PD Study - TradingView
Rallybio begins dosing in phase 1 study of C5 inhibitor RLYB116 By Investing.com - Investing.com South Africa
Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study - BioSpace
Rallybio begins dosing in phase 1 study of C5 inhibitor RLYB116 - Investing.com India
Rallybio Initiates Dosing In RLYB116 Phase 1 Confirmatory Study - MarketScreener
Rallybio's $5B Market Opportunity: New Phase 1 Trial Targets Two Untreated Rare Blood Disorders - Stock Titan
RLYBRallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial - mx.advfn.com
Connecticut biotech shows resilience amid recent layoffs at Arvinas, RallyBio - Trumbull Times
Rallybio’s SWOT analysis: C5 inhibitor focus shifts stock outlook By Investing.com - Investing.com Canada
Rallybio’s SWOT analysis: C5 inhibitor focus shifts stock outlook - Investing.com
Rallybio shareholders elect directors, ratify auditor By Investing.com - Investing.com Nigeria
Rallybio shareholders elect directors, ratify auditor - Investing.com
Rallybio Elects New Directors at Shareholder Meeting - TipRanks
Rallybio Reports Q1 2025 Financial Results and Strategic Updates - MSN
New Haven biotech firm to cut 40% of workforce in latest round of layoffs, pivots on drug program - Stamford Advocate
Rallybio Downsizes by 40% After Dropping Lead Asset - BioSpace
Layoffs hit biotech: Vor Bio slashes 95% of staff, more cuts from insitro, Korro, Rallybio - FirstWord Pharma
4 more biotechs cut staff amid market tumult - BioPharma Dive
Rallybio Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Another CT biotech company making significant workforce cuts - Hartford Business Journal
RallyBio cuts deeper, laying off 40% of workforce after halting work on lead drug - Fierce Biotech
Rallybio Corp SEC 10-Q Report - TradingView
Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates - Bluefield Daily Telegraph
Rallybio (RLYB) to Release Quarterly Earnings on Thursday - Defense World
Renaissance Technologies LLC Has $424,000 Stock Position in Rallybio Co. (NASDAQ:RLYB) - Defense World
Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference - BioSpace
Rallybio Makes Nasdaq Debut - RTTNews
Citizens JMP maintains Rallybio stock at Market Perform By Investing.com - Investing.com Nigeria
Citizens JMP maintains Rallybio stock at Market Perform - Investing.com
Rallybio (NASDAQ:RLYB) Cut to Hold at Evercore ISI - Defense World
Rallybio drops drug for rare maternal disorder following Phase II fail - MSN
This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Evercore ISI Downgrades Rallybio to In Line From Outperform - marketscreener.com
Analysts Set Rallybio Co. (NASDAQ:RLYB) Price Target at $9.75 - Defense World
Evercore ISI cuts Rallybio stock rating on study concerns - Investing.com Australia
HC Wainwright Estimates Rallybio’s Q2 Earnings (NASDAQ:RLYB) - Defense World
Rallybio’s (RLYB) Neutral Rating Reiterated at HC Wainwright - Defense World
Evercore ISI cuts Rallybio stock rating on study concerns By Investing.com - Investing.com India
Rallybio (NASDAQ:RLYB) Cut to Hold at Citizens Jmp - Defense World
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks - Yahoo Finance
Rallybio Corp (RLYB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.23%
2.91%
자본화:
|
볼륨(24시간):